15 May 2002
Hepatitis B vaccine immunogenicity in patients with chronic HCV infection atone year follow-up: the effect of interferon-alpha therapy.
Anna Grzeszczuk, Sławomir Chlabicz, Tadeusz Wojciech ŁapińskiMed Sci Monit 2002; 8(5): CR379-383 :: ID: 420833
Abstract
BACKGROUND: Patients with chronic hepatitis C are at risk of additionalliver damage when infected with other hepatotropic viruses, and should be vaccinated against HAV andHBV. However, the optimal dose and schedule are still being debated. In this study we assessed hepatitisB vaccine immunogenicity in patients with chronic hepatitis C at one-year follow-up. The effect of interferonalpha treatment on vaccine safety and anti-HBs response was also evaluated. MATERIAL/METHODS: 48 hepatitisC patients were enrolled, of whom 12 were on interferon treatment. Recombinant HBV vaccine was administeredon a 0-1-6 month schedule, and anti-HBs titers were measured at months 1, 2, 7, and 18. RESULTS: Theoverall seroprotection rate at month 7 was 72.9% in hepatitis C patients, compared to 90.9% in the controls.Subjects with chronic hepatitis C had significantly lower percentages of good responders: 50% versus90.9%. At month 18, only 34.1% of the HCV patients had seroprotective titers of anti-HBs, compared to90% in the control group. At all study points there were no significant differences in seroconversionrates and seroprotection rates between subgroups of hepatitis C patients receiving interferon or thosewithout antiviral treatment. CONCLUSIONS: Hepatitis C is associated with decreased HBV vaccine response.We suggest that postvaccination anti-HBs testing should be performed in all hepatitis C patients, andadditional vaccine doses should be provided to those without protection. Alternatively, higher dosesof vaccine (40 Kg) may be considered. Treatment with interferon was safe and well tolerated.
Keywords: Hepacivirus, Hepatitis B Antibodies, Hepatitis B Vaccines, Hepatitis C, Hepatitis C Antibodies, Interferon-alpha, Interferons, Liver, Recombinant Proteins, Time Factors
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
08 Mar 2024 : Laboratory Research
Evaluation of Retentive Strength of 50 Endodontically-Treated Single-Rooted Mandibular Second Premolars Res...Med Sci Monit In Press; DOI: 10.12659/MSM.944110
11 Mar 2024 : Clinical Research
Comparison of Effects of Sugammadex and Neostigmine on Postoperative Neuromuscular Blockade Recovery in Pat...Med Sci Monit In Press; DOI: 10.12659/MSM.942773
12 Mar 2024 : Clinical Research
Comparing Neuromuscular Blockade Measurement Between Upper Arm (TOF Cuff®) and Eyelid (TOF Scan®) Using Miv...Med Sci Monit In Press; DOI: 10.12659/MSM.943630
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952